Souhaitez-vous accéder aux communiqués récents ?

SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today announced that selling stockholders affiliated with Blackstone Inc. (the “Selling...

LAFAYETTE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (Nasdaq: UGRO) ("urban-gro" or the "Company"), today furnished an investor presentation via a Current Report on Form 8-K,...

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an...

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq:...

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that...

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory...

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Long-Term Financing by Oberland Capital

Agios will report its first quarter 2026 financial results and business highlights on Wednesday, April 29, 2026.

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —  RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) --...

SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...